- Title
- Concomitant Use of Triptan, and SSRI or SNRI After the US Food and Drug Administration Alert on Serotonin Syndrome
- Creators
- David A SCLAR - Pharmacoeconomics and Pharmacoepidemiology Research Unit, College of Pharmacy, Washington State University, Spokane, WA, United StatesLinda M ROBISON - Pharmacoeconomics and Pharmacoepidemiology Research Unit, College of Pharmacy, Washington State University, Spokane, WA, United StatesLeigh V CASTILLO - Pharmacoeconomics and Pharmacoepidemiology Research Unit, College of Pharmacy, Washington State University, Spokane, WA, United StatesJennifer M SCHMIDT - Pharmacoeconomics and Pharmacoepidemiology Research Unit, College of Pharmacy, Washington State University, Spokane, WA, United StatesKurt A BOWEN - Pharmacoeconomics and Pharmacoepidemiology Research Unit, College of Pharmacy, Washington State University, Spokane, WA, United StatesAmbartsum M OGANOV - Pharmacoeconomics and Pharmacoepidemiology Research Unit, College of Pharmacy, Washington State University, Spokane, WA, United StatesTracy L SKAER - Pharmacoeconomics and Pharmacoepidemiology Research Unit, College of Pharmacy, Washington State University, Spokane, WA, United StatesStephen J KOGUT - Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island, Kingston, RI, United States
- Publication Details
- Headache, Vol.52(2), pp.198-203
- Academic Unit
- Pharmacotherapy, Department of
- Publisher
- Wiley-Blackwell; Malden, MA
- Identifiers
- 99900546929701842
- Language
- English
- Resource Type
- Journal article
Journal article
Concomitant Use of Triptan, and SSRI or SNRI After the US Food and Drug Administration Alert on Serotonin Syndrome
Headache, Vol.52(2), pp.198-203
2012
Handle:
https://hdl.handle.net/2376/105635
PMID: 22289074
Abstract
Metrics
8 Record Views